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Acinetobacter baumannii is an aerobic Gram-negative coccobacillus that causes nosocomial pneumonia in patients on me-
chanical ventilation or previously treated with broad-spectrum antibiotics. Nevertheless, community-acquired pneumonia (CAP) 
caused by A. baumannii, especially multi-drug resistant (MDR) strains, is rare. We experienced the first case of CAP caused by 
MDR A. baumannii in Korea in a 78-year-old man. This case shows that MDR A. baumannii can cause CAP in Korea.
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Case Report
Introduction 
Acinetobacter baumannii is an aerobic Gram-negative coc-
cobacillus [1]. It causes nosocomial pneumonia, especially in 
patients on mechanical ventilation or after treatment with 
broad-spectrum antibiotics [1, 2]. Interestingly, communi-
ty-acquired pneumonia (CAP) caused by A. baumannii has a 
higher mortality rate than that of hospital-acquired pneumo-
nia (HAP), although CAP caused by A. baumannii, especially 
multi-drug resistant (MDR) A. baumannii, is rare [3]. Recent-
ly, MDR A. baumannii has increased as an emerging problem 
because of restricted therapeutic options [4]. Here, we report 
the first case of CAP caused by MDR A. baumannii in Korea 
in a 78-year-old man.
Case Report
A 78-year-old man presented to the emergency department 
with dyspnea and fever for 6 hours. He was not currently em-
ployed and had no history of cigarette smoking or alcohol in-
gestion. He had no underlying disease. Besides, he had no 
hospital admission, antimicrobial use history and healthcare 
institution visiting record in 1 year. On admission, he ap-
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peared acutely ill. His blood pressure was 104/57 mmHg, re-
spiratory rate 20 breaths per minute, pulse rate 110 beats per 
minute, and body temperature 38.2°C. A regular heart rhythm 
was observed. There were coarse breath sounds with crackles 
in the right lung field. 
The laboratory results were as follows: white blood cell 
count 3,900/mm3 (72.5% neutrophils, 20.4% lymphocytes, 
4.7% monocytes, 2.82% eosinophils), hemoglobin 12.2 g/dL, 
platelet count 197,000/mm3, C-reactive protein 1.24 mg/dL, 
blood urea nitrogen 28.2 mg/dL, creatinine 1.24 mg/dL, as-
partate aminotransferase 16 UI/L, alanine aminotransferase 
10 IU/L, total bilirubin 0.9 mg/dL, total protein 6.0 g/dL, and 
albumin 3.5 g/dL. The arterial blood gas analysis breathing 
room air was pH 7.44, pCO2 24.1 mmHg, pO2 59.0 mmHg, HCO3
– 
17 mmol/L, and O2 saturation 87%. A plain chest radiograph 
showed patchy consolidations in the right middle and lower 
lobes (Fig. 1A). Chest computed tomography (CT) showed lobar 
pneumonia in the right middle and lower lobes (Fig. 2A). He 
was diagnosed with CAP. Intravenous piperacillin/tazobactam 
and ciprofloxacin were administered empirically.
Five hours after admission, his respiratory distress wors-
ened, and he was treated with oxygen at 6 L/min via mask. On 
the second day after admission, intravenous teicoplanin was 
administered because of a persistent fever. On the third day, A. 
Figure 1. Chest radiography. (A) The chest radiograph on admission showed lobar pneumonia in the right upper and middle lobes. (B) On the 48th day 
after admission, the chest radiograph showed improvement in the consolidations of the right and middle lobes.
A B
Figure 2. Chest computed tomography (CT). (A) On admission, CT showed lobar pneumonia in the right upper and middle lobes with a parapneumonic 
effusion. (B) At the 48th day after admission, CT showed improvement in the consolidations of the right upper and middle lobes.
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baumannii was identified in cultures of both sputum and in 
two of three pairs of blood samples taken on admission. A. 
baumannii was identified using Matrix-assisted laser desorp-
tion/ionization time-of-flight mass spectrometry (MAL-
DI-TOF MS, Bruker Daltonics GmbH, Bremen, Germany) on a 
Microflex spectrometer (Bruker Daltonics GmbH, Germany). 
Antimicrobial susceptibilities were determined using VITEK-2 
system (bioMerieux, Marcy I’Etoile, France). The bacterial iso-
late was resistant to multiple drugs, except colistin, tigecy-
cline, minocycline, amikacin, and gentamicin (Table 1). 
Therefore, the antibiotics were changed to intravenous colistin 
and oral minocycline.
On the 6th day after admission, his vital signs stabilized and 
the fever subsided. Follow-up chest radiography and CT 
showed improved consolidation. No A. baumannii grew in 
the follow-up blood cultures. On the 26th day after admission, 
because of colistin-induced nephropathy, the antibiotics were 
switched to tigecycline. On the 48th day after admission, the 
chest radiograph and chest CT showed that the pneumonia 
had improved (Fig.1B and 2B). The patient was discharged on 
day 56 and followed as an outpatient with no significant com-
plications.
Discussion
Organisms in the genus Acinetobacter were isolated and 
first described by the microbiologist Beijerinck in 1911 [2]. A. 
baumannii is an aerobic Gram-negative coccobacillus that 
occurs in fresh water and soil [1]. A. baumannii is regarded as 
a significant pathogen causing nosocomial pneumonia [1, 2]. 
By contrast, community-onset A. baumannii infection is un-
common and usually occurs in patients with solid tumor, pri-
or receipt of antimicrobial agents within 30 days and central 
venous catheterization [5]. Especially CAP caused by A. bau-
mannii tends to progress rapidly to a fulminate clinical course 
[1-3, 6]. Recently, the incidence of carbapenem-resistant A. 
baumannii has increased [7, 8].
Five cases of CAP caused by A. baumannii have been re-
ported in Korea; in all cases, A. baumannii was identified in 
sputum cultures, blood cultures, or biopsy. Fortunately, the A. 
baumannii was susceptible to piperacillin/tazobactam, cef-
tazidime, cefepime, meropenem, and tobramycin [9-13]. In 
our case, susceptibility tests showed that the A. baumannii 
was resistant to piperacillin/tazobactam, ceftazidime, 
cefepime, imipenem, meropenem, and tobramycin but sus-
ceptible to colistin, tigecycline, minocycline, amikacin, and 
gentamicin.
Although this is the first reported case of CAP caused by 
MDR A. baumannii in Korea, it is expected to increase with 
the incidence of MDR A. baumannii. MDR A. baumannii 
should be considered if empirical antibiotics do not work in 
CAP. Recommended empirical antibiotics for CAP caused by 
A. baumannii include anti-pseudomonal penicillins, cipro-
floxacin, aminoglycoside, and imipenem [14-16]. However, A. 
baumannii resistance to carbapenem has increased recently, 
limiting the treatment options [4]. MDR A. baumannii has few 
treatment options and a poor prognosis, although colistin, 
tigecycline, or minocycline are options [16-18]. Our patient 
responded to colistin (with minocycline) and tigecycline, de-
spite a long treatment period.
This case is an example of the successful treatment of CAP 
caused by MDR A. baumannii, in a patient without medical 
comorbidities, and is the first reported case of CAP caused by 
MDR A. baumannii in Korea. MDR A. baumannii should be 
considered as a pathogen causing community-acquired pneu-
monia, and further epidemiological studies are needed to 
control infection.
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Table 1. The antibiotic susceptibility of the Acinetobacter baumannii  isolate
Antibiotic MIC Susceptibility
Ampicillin/sulbactam ≥32 R
Ceftazidime 4 R
Ciprofloxacin ≥4 R
Colistin ≤0.5 S
Cefepime ≥64 R
Cefotaxime 32 I
Gentamicin ≤1 S
Imipenem ≥16 R
Levofloxacin ≥8 R
Meropenem ≥16 R
Minocycline ≤1 S
Piperacillin ≥128 R
Piperacillin/tazobactam ≥128 R
Trimethoprim/sulfamethoxazole 160 R
Tigecycline ≤0.5 S
MIC, minimum inhibitory concentration; R, resistant; I, intermediate resistance; S, 
susceptible
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